Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of PAT DX1

Next Previous
Trial Profile

A clinical trial of PAT DX1

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PAT DX1 (Primary)
  • Indications Cancer
  • Focus Adverse reactions; First in man

Most Recent Events

  • 20 Apr 2026 According to a Patrys media release, the company has raised approximately A dollar 3.2 million via a share placement, the funds will be used for the use of funds outlined by the company, including advancing key clinical development milestones and progressing toward a first-in-human Phase 1a clinical trial.
  • 14 Dec 2023 According to a Patrys media release, company will initiate this first-in-human clinical trial of PAT-DX1 in the second half of CY 2024.
  • 24 Apr 2023 According to a Patrys media release, company is expecting to initiate this trial in calendar year 2024 due to sporadic issue in the most recent production run of clinical grade PAT-DX1.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top